Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Leukemia 2Thrombocythemia, Essential 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neuroblastoma 1Leukemia, Myeloid 1Leukemia, Biphenotypic, Acute 1Congenital Abnormalities 1

Interventions

Peripheral Blood Stem Cell Transplantation 18fludarabine phosphate 17Cyclophosphamide 17Busulfan 12Tacrolimus 11Methotrexate 8Cyclosporine 8Antilymphocyte Serum 8Whole-Body Irradiation 7Mycophenolic Acid 7Filgrastim 6peginterferon alfa-2a 5Etoposide 5Prednisone 4Decitabine 4Cytarabine 4ruxolitinib 3fludarabine 3Radiotherapy 3Methylprednisolone 3Carboplatin 3Aspirin 3tipifarnib 2sonidegib 2merphos 2liposomal amphotericin B 2givinostat hydrochloride 2givinostat 2aldesleukin 2Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Thrombocythemia, Essential × lestaurtinib × Clear all
NCT00586651 2015-10-08

Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
39 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

Data powered by HemOnc (CC BY 4.0) Colophon âš¡